好医生云医疗毛利率大降：家族式控股，关联采购持续激增

Core Viewpoint - Sichuan Good Doctor Cloud Medical Technology Group Co., Ltd. has submitted an IPO application to the Hong Kong Stock Exchange, marking a significant step despite its history of losses until 2022, when it finally turned profitable. However, the company faces concerns regarding family control and increasing related-party transactions [1][13]. Financial Performance - The company reported revenues of 18.82 billion, 30.65 billion, 32.64 billion, and 18.91 billion from 2022 to the first half of 2025, with year-on-year growth rates of 62.8%, 6.5%, and 23.9% respectively [3][15]. - Despite revenue growth, the company recorded a cumulative loss of 5610 million as of June 30, 2025, primarily due to historical losses since its establishment [3][16]. - The gross profit margin has shown a declining trend, with overall margins of 20.5%, 29.9%, 26.4%, and 22.8% during the reporting period, reflecting a decrease of 6.2 percentage points in the first half of 2024 [4][16]. Revenue Sources - The main revenue source is the pharmaceutical supply chain solutions, contributing 90.4%, 79.9%, 77.5%, and 78.1% of total revenue from 2022 to the first half of 2025. This segment includes proprietary and generic drug businesses [2][15]. - The specialized disease diagnosis solutions also contributed significantly, with revenues of 5.07 billion, 6.67 billion, and 3.79 billion, accounting for 16.5%, 20.4%, and 20.1% of total revenue during the same period [2][15]. Operational Costs - Sales and marketing expenses have been substantial, amounting to 2.62 billion, 7.47 billion, 6.98 billion, and 3.07 billion, representing 13.91%, 24.37%, 21.38%, and 16.22% of total revenue [6][17]. - Administrative expenses were significantly lower, at 923.85 million, 924.66 million, 969.06 million, and 631.60 million, accounting for 4.91%, 3.02%, 2.97%, and 3.34% of total revenue [6][18]. Inventory and Cash Flow - The company's inventory levels increased significantly, with values of 2.56 billion, 4.64 billion, 6.03 billion, and 5.11 billion, leading to longer inventory turnover days [7][19]. - The net cash flow from operating activities was negative in 2022, with subsequent positive cash flows in later periods, indicating fluctuating liquidity [8][20]. Family Control and Related Transactions - The company is under significant family control, with major shareholders holding approximately 65.99% of voting rights, raising concerns about governance and potential conflicts of interest [9][21]. - Related-party transactions have increased, with purchases from a major supplier, Sichuan Jiananda, rising to 16.7% of total procurement in recent periods [12][24]. Future Plans - The IPO proceeds are intended for national expansion of core business, development of a robust R&D environment, potential strategic investments, and general corporate purposes [12][24].